SEC Form 4 · accession 0000899243-19-000302
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thorlef Spickschen
Director
Period of report
Jan 3, 2019
Accepted (ET)
Jan 3, 2019 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 3, 2019 | M | 6,896 | $3.08 | A | 14,514 | D | |
| Common Stock | Jan 3, 2019 | M | 25,862 | $0.29 | A | 40,376 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.08 | Jan 3, 2019 | M | 6,896 | D | — | Dec 2, 2020 | Common Stock | 6,896 | 0 | D |
| Stock Option (right to buy)F1 | $0.29 | Jan 3, 2019 | M | 25,862 | D | — | Aug 26, 2019 | Common Stock | 25,862 | 0 | D |
Explanation of responses
- F1The option was exercisable as of the reporting person's previous filing on Form 3, dated as of November 15, 2011.